It's impossible to speculate as to how things will play out in...

It's impossible to speculate as to how things will play out in the future as the future always remains uncertain. The big positives with it though is Elotuzumab as a single agent in Phase I studies actually had a lower SD response than SM6 has shown although a slightly larger sized trial - 26.5% (9 of 35 patients) VS 33% (4 of 12 patients). The real driver for Elotuzumab came through combination with lenalidomide and low-dose dexamethasone in later trials which shows again the powers that remain in combining different treatments. Although we still know very little such as the scope of the proposed Onyx/Patrys trials & how long that will be from start to finish which is when we really see the data generated.

Just on the last post in reference to NK cells here's two quick snippets, the first in reference to Elotuzumab & the second SM6.

"Elotuzumab is a humanized IgG1 monoclonal antibody targeted against Signaling Lymphocyte Activation Molecule (SLAMF7, also called CS1), a glycoprotein expressed on myeloma and Natural Killer cells but not detectable in normal tissue. The company is investigating whether through both direct activation and engagement of Natural Killer cells, elotuzumab may selectively target and kill SLAMF7 expressing myeloma cells."



"Furthermore analysis of patient’s immune systems indicated that PAT-SM6 is capable of inducing an immune response by both stimulating and increasing the absolute number of CD8+, NK and regulatory T-cells. These cells are specifically capable of regulating the growth and dissemination of tumours. Such changes were more significant in patients who had experienced stable disease post treatment with PAT-SM6. These data may indicate specific crosstalk between PAT-SM6 and immune cells, a previously unreported finding that warrants further investigation.